Led by AI strategist James Hill, the platform uses multiple specialized AI models to manage sequence optimization, structural prediction, toxicity screening, and binding analysis, enabling rapid assessment of large genetic and protein datasets from databases like NCBI GenBank and UniProt.

The company operates three divisions—manufacturing, discovery, and diagnostics—with revenue from a research lab serving around 40 customers in Australia and New Zealand, and a diagnostics arm focused on rapid point-of-care tests and building distribution for future products.

Perth-based Syngenis Laboratories is launching an AI-powered discovery platform, Syngenis Discovery, designed to accelerate drug and diagnostic molecule development by evaluating billions of molecular combinations and compressing discovery timelines from months or years to hours.

The platform targets rapid identification of therapeutic and diagnostic molecules by screening vast molecular libraries and leveraging advanced AI to explore billions of combinations.

Leadership blends biotech, AI, and commercialization expertise, led by Prof. Rakesh Veedu (nucleic acid therapeutics), AI strategist James Hill, and MD Thomas Hanly, who plans an ASX listing later this year to fund growth.

The team combines nucleic acid therapeutics, AI strategy, and healthcare commercialization to position Syngenis for accelerated growth and public market funding.

The platform focuses on oligonucleotide therapeutics and aptamer discovery, leveraging RNA/DNA-based medicines with potential applications in cancer, neurological, inflammatory, and genetic diseases.

Syngenis positions Australia to take a leading role at the intersection of biology, chemistry, and AI amid a broader AI-driven biotech shift.

Syngenis envisions the platform helping researchers save time and money by identifying near-optimized sequences before manufacturing, potentially accelerating therapeutic development and diagnostic product rollout.

Syngenis Discovery analyzes data to optimize sequences, predict structures, screen for toxicity, and assess binding, enabling rapid generation and evaluation of large molecular libraries while preserving essential wet-lab work.

The company intends to support and expedite discovery before manufacturing, narrowing the search space prior to costly lab work, with an ASX float planned later this year to fund expansion into AI-driven biotechnology and clinical manufacturing.

By combining advanced computation with molecular science, Syngenis aims to gain a competitive edge in discovery speed and commercialization, highlighting Australia’s prominence in next-generation biotechnology.